Table 16:
Treat-and-Extend PRN Re-treatment Protocols for n-AMD on Outcomes in A-VEGF Trials
| Study, Author, Year | Δ BCVA Letters Mean ± SD | Proportion (%) Gaining ≥ 15 BCVA Letters | Proportion (%) Losing ≥ 15 BCVA Letters | Δ CRT (μm) Mean ± SD | # Visits Mean ± SD (Range) 12 Months | # Injections Mean ± SD (Range) 12 Months |
|---|---|---|---|---|---|---|
| Ernst et al, 2010 (76) | 1.6 ± 2.9 (Snellen) 8 letters | 36 | 12 | –43 | NR | 6.0 ± 2.7 (3–12) Over 16 months |
| LAST, Fung et al, 2012 (77) High- vs. low-dose ranibizumab | 4.1 ± 4.5 vs. 3.0 | NR | NR | –28 ± 46 vs. −73 | NR | 6.0 vs. 5.0 |
| Oubraham et al, 2011 (78) | ||||||
| PRN group | 2.3 ± 17.4 | NR | NR | NR | 8.8 ± 1.5 (6–13) | 5.2 ± 1.9 (3–10) |
| Treat-and-extend group | 10.8 ± 8.8 | NR | NR | NR | 8.5 ± 1.1 (7–12) | 7.8 ± 1.3 (6–11) |
Abbreviations: BCVA, best corrected visual acuity; CRT, central retinal thickness; NR, not reported; PRN, pro re nata (as needed); SD, standard deviation.